4.7 Article

18F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 53, Issue 9, Pages 1337-1344

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.111.098640

Keywords

F-18-FDG PET/CT; lymph nodes; SUV; breast cancer; prognosis

Funding

  1. Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) [2011-0006331]
  2. Ministry of Education, Science and Technology (MEST)
  3. Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A102132]
  4. Brain Korea 21 Project
  5. Korea Health Promotion Institute [A102132] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

This study assessed the maximum standardized uptake value of metastatic axillary lymph nodes in patients with invasive ductal breast cancer (IDC) to determine the pretreatment prognostic value of F-18-FDG PET/CT for disease-free survival (DFS). Methods: Sixty-five female IDC patients who had undergone pretreatment F-18-FDG PET/CT and had pathologically confirmed axillary lymph node involvement without distant metastasis were enrolled. All patients showed complete remission after first-line treatment. To obtain nodal SUVmax, a transaxial image representing the highest F-18-FDG uptake was carefully selected and a region of interest was manually drawn on the F-18-FDG-accumulating lesion. Clinicopathologic parameters such as age, TNM stage, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and primary-tumor and nodal SUVmax on PET were analyzed for their usefulness in predicting recurrence. Combinatorial effects and interactions between variables that were significant by univariate analysis were examined using multivariate Cox proportional-hazards models. Results: Twelve of 65 patients (18.5%) experienced recurrence during follow-up (median follow-up, 36 mo; range, 21-57 mo). Nodal SUVmax was significantly higher in patients with recurrence than in those who were disease-free (recurrence group: 5.2 +/- 2.3, vs. disease-free group: 1.9 +/- 1.9, P < 0.0001). A receiver-operating-characteristic curve demonstrated a nodal SUVmax of 2.8 (sensitivity, 91.7%; specificity, 86.8%; area under the curve, 0.890) to be the optimal cutoff for predicting DFS. Univariate analysis revealed that T stage, N stage, estrogen receptor status, and primary-tumor and nodal SUVmax correlated significantly with DFS. Among these 5 variables, only nodal SUVmax was found to be a single determinant of DFS by multivariate analysis (hazard ratio, 31.54; 95% confidence interval, 2.66-373.39; P = 0.0065). Conclusion: Nodal SUVmax on pretreatment F-18-FDG PET/CT may be an independent prognostic factor for disease recurrence in patients with IDC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available